News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,005 Results
Type
Article (40028)
Company Profile (250)
Press Release (664726)
Multimedia
Podcasts (60)
Webinars (14)
Section
Business (204290)
Career Advice (2011)
Deals (35454)
Drug Delivery (96)
Drug Development (81141)
Employer Resources (172)
FDA (16252)
Job Trends (14889)
News (345523)
Policy (32610)
Tag
Academia (2556)
Accelerated approval (10)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (109)
Alzheimer's disease (1445)
Antibody-drug conjugate (ADC) (151)
Approvals (16248)
Artificial intelligence (311)
Autoimmune disease (28)
Automation (19)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (123)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (34)
Breast cancer (367)
Cancer (2877)
Cardiovascular disease (213)
Career advice (1682)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (500)
Cervical cancer (22)
Clinical research (66870)
Collaboration (1017)
Company closure (3)
Compensation (690)
Complete response letters (23)
COVID-19 (2624)
CRISPR (57)
C-suite (330)
Cystic fibrosis (113)
Data (3013)
Decentralized trials (2)
Denatured (20)
Depression (61)
Diabetes (346)
Diagnostics (6426)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (138)
Drug pricing (122)
Drug shortages (28)
Duchenne muscular dystrophy (130)
Earnings (87469)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113751)
Executive appointments (846)
FDA (17914)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (933)
Gene editing (131)
Generative AI (22)
Gene therapy (375)
GLP-1 (783)
Government (4504)
Grass and pollen (4)
Guidances (182)
Healthcare (18843)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (148)
Immuno-oncology (9)
Indications (39)
Infectious disease (2796)
Inflammatory bowel disease (149)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (120)
Interviews (312)
IPO (16591)
IRA (45)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (53)
Layoffs (495)
Leadership (19)
Legal (7932)
Liver cancer (79)
Longevity (11)
Lung cancer (402)
Lymphoma (209)
Machine learning (11)
Management (58)
Manufacturing (390)
MASH (91)
Medical device (13465)
Medtech (13470)
Mergers & acquisitions (19585)
Metabolic disorders (850)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (116)
Neuropsychiatric disorders (32)
Neuroscience (2125)
NextGen: Class of 2025 (6520)
Non-profit (4489)
Now hiring (48)
Obesity (428)
Opinion (217)
Ovarian cancer (101)
Pain (107)
Pancreatic cancer (121)
Parkinson's disease (186)
Partnered (22)
Patents (302)
Patient recruitment (167)
Peanut (50)
People (57699)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20832)
Phase II (29453)
Phase III (21923)
Pipeline (1645)
Policy (202)
Postmarket research (2563)
Preclinical (8872)
Press Release (64)
Prostate cancer (140)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (460)
Real estate (5917)
Recruiting (66)
Regulatory (22644)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (157)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3588)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (58)
The Weekly (38)
Vaccines (779)
Venture capital (54)
Weight loss (257)
Women's health (47)
Worklife (16)
Date
Today (80)
Last 7 days (344)
Last 30 days (1794)
Last 365 days (31161)
2025 (16884)
2024 (35219)
2023 (40078)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46539)
2018 (35026)
2017 (32112)
2016 (31480)
2015 (37552)
2014 (31319)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27329)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (244)
Arkansas (13)
Asia (38220)
Australia (6233)
California (7454)
Canada (2365)
China (672)
Colorado (320)
Connecticut (319)
Delaware (192)
Europe (82120)
Florida (1121)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (639)
India (27)
Indiana (361)
Iowa (17)
Japan (229)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1027)
Massachusetts (5539)
Michigan (246)
Minnesota (452)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (66)
New Jersey (2082)
New Mexico (28)
New York (2089)
North Carolina (1082)
North Dakota (8)
Northern California (3282)
Ohio (237)
Oklahoma (16)
Oregon (34)
Pennsylvania (1615)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2792)
Tennessee (126)
Texas (1127)
United States (27628)
Utah (220)
Virginia (187)
Washington D.C. (72)
Washington State (634)
West Virginia (4)
Wisconsin (66)
705,005 Results for "anthem inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
Protagonist Therapeutics, Inc. today announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to evaluate the safety and effectiveness of JNJ-2113 compared with placebo in participants with moderately to severely active ulcerative colitis.
December 13, 2023
·
5 min read
BioMidwest
Relievant Medsystems Announces Positive Coverage Policy for the Intracept Procedure from Anthem Blue Cross and Blue Shield
Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced that Anthem Blue Cross and Blue Shield has established favorable coverage for the Intracept® Procedure.
October 3, 2023
·
3 min read
Biotech Beach
MicroVascular Tissues’ mVASC(R) Microvascular Tissue Allograft Covered by Anthem and Amerigroup
MicroVascular Tissues, Inc., a regenerative tissue company, announces effective 12/28/2022, Anthem Blue Cross Blue Shield and Amerigroup added coverage of mVASC® Microvascular Tissue Allograft for the treatment of diabetic foot ulcers.
April 25, 2023
·
1 min read
BioCapital
Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem
Senseonics Holdings, Inc. today announced that Anthem is providing coverage for implantable CGM, which includes the Eversense® CGM System.
August 3, 2022
·
5 min read
Press Releases
Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
May 12, 2025
·
5 min read
Press Releases
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
July 16, 2025
·
5 min read
Press Releases
Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
July 16, 2025
·
5 min read
Press Releases
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
July 15, 2025
·
13 min read
INSIGHTEC ANNOUNCES POSITIVE COVERAGE DECISION BY ANTHEM FOR MR-GUIDED FOCUSED ULTRASOUND TO TREAT ESSENTIAL TREMOR
Insightec®, a global healthcare company dedicated to using acoustic energy to transform patient care, announced today that Anthem is the third national payor to cover MR-guided Focused Ultrasound for treating medication-refractory Essential Tremor.
December 22, 2022
·
3 min read
Press Releases
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
March 11, 2025
·
5 min read
1 of 70,501
Next
